Evidence map›Paper›PMID 15655502›Full record

ArticleBritish journal of pharmacology2005

Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs.

Giuseppe Rossoni, Barbara Manfredi, Roberta Razzetti, Maurizio Civelli, Stefano Bongrani, Ferruccio Berti

2 registry-linked trialsOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00605891 phase2completednot on this mapstarted 2006, after this paper: background citation

A Randomized, Controlled,14-Treatment Day, Multicenter Study to Determine the Optimal Efficacious and Safe Dose of CHF 4226 in a Metered Dose Inhaler in Treating Patients With Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorChiesi Farmaceutici S.p.A.Ran2006 to 2007Enrolled278ConditionsChronic Obstructive Pulmonary DiseaseArmscarmoterol (CHF 4226), salmeterol, placebo
NCT00640484 phase2completednot on this mapstarted 2008, after this paper: background citation

Evaluation of the Effect of 2 Weeks Treatment With CHF 4226 pMDI 2µg and 4µg, Given Once Daily in the Morning, on 24-Hour FEV1 in Patients With COPD

TypeinterventionalSponsorChiesi Farmaceutici S.p.A.Ran2008 to 2008Enrolled57ConditionsChronic Obstructive Pulmonary DiseaseArmscarmoterol (CHF 4226), placebo, salmeterol
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Novel long-acting bronchodilators for COPD and asthma.British journal of pharmacology · 2008
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Giuseppe RossoniDepartment of Pharmacological Sciences, University of Milan, Milan, Italy, USA. giuseppe.rossoni@unimi.it
Barbara Manfredi
Roberta Razzetti
Maurizio Civelli
Stefano Bongrani
Ferruccio Berti
Chiesi (Italy) · ITUniversity of Milan · ITOspedale San Giuseppe · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pretreatment of anaesthetized guinea-pigs with either CHF 4226.01 (8-hydroxy-5-[(1R)-1-hydroxy-2-[N-[(1R)-2-(p-methoxyphenyl)-1-methylethyl]amino]ethyl] carbostyril hydrochloride), formoterol or budesonide reduced acetaldehyde (AcCHO)-evoked responses in the lungs with a rank order of potency CHF 4226.01 (ED(50) values, from 1.88 to 3.31 pmol) > formoterol (ED(50) values, from 3.03 to 5.51 pmol) >> budesonide (ED(50) values, from 335 to 458 nmol). The duration of action of CHF 4226.01 in antagonizing the airway obstruction elicited by AcCHO was also substantially longer than formoterol (area under the curve) at 10 pmol, 763+/-58 and 480+/-34, respectively; P<0.01). Continuous infusion of a subthreshold dose of AcCHO enhanced the intratracheal pressure (ITP) increases caused by subsequent challenges with substance P (from 9.7+/-0.8 to 27.5+/-1.6 cm H(2)O as a peak, P<0.001). Pretreatment with either CHF 4226.01 or formoterol prevented the sensitizing effect of AcCHO on substance P responses (ED(50) values, 2.85 and 6.11 pmol, respectively; P<0.01). The ED(50) value of budesonide (396 nmol) in preventing AcCHO-evoked ITP increase was reduced when this glucocorticoid was combined with 0.1 pmol CHF 4226.01 (ED(50) 76 nmol; P<0.001). CHF 4226.01/budesonide was two-fold more effective (P<0.01) than the formoterol/budesonide combination. These results suggest that CHF 4226.01/budesonide, by optimizing each other's beneficial potential in the control of pulmonary changes caused by AcCHO in the guinea-pigs, may represent a new fixed combination in asthma.

Indexed as

Adrenergic beta-2 Receptor AgonistsAcetaldehydeAdrenergic beta-AgonistsAmphetaminesAnimalsBronchoconstrictionBronchodilator AgentsBudesonideCapillary PermeabilityDose-Response Relationship, DrugDrug SynergismEthanolaminesEthylaminesFormoterol FumarateGuinea PigsHistamineAcetaldehydeAdrenergic beta-2 Receptor AgonistsAdrenergic beta-AgonistsAmphetaminesBronchodilator AgentsBudesonidecarmoterolEthanolaminesEthylaminesFormoterol FumarateHistamineHydroxyquinolinesInosine TriphosphateQuinolonesSubstance P

Identifiers

PMID15655502
PMCPMC1576020
OpenAlexW2166483979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.